A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Stopped The FDA declined to grant Breakthrough Therapy designation or support an Accelerated Approval pathway based on the EQUATOR study data.
Conditions
- Graft Versus Host Disease
- GVHD
- Acute-graft-versus-host Disease
- Acute GVHD
- aGVHD
Interventions
- BIOLOGICAL: Itolizumab
- DRUG: EQ001 Placebo
Sponsor
Equillium
Collaborators